Novo Nordisk broke ground on its new $1 .8 billion diabetes medicine production facility in Clayton, the company said more than 100 community members, employees and policymakers attended a ceremonial event with Lars Rebien Sørensen, president and chief executive officer of Novo Nordisk, and Gov. Pat McCrory.
The facility will produce active pharmaceutical ingredients (API) for a range of Novo Nordisk’s current and future GLP-1 and insulin medicines. Once fully operational in 2020, the Clayton facility will ensure production capacity for diabetes medicines in the U.S. for the decade ahead.
Novo Nordisk’s billion dollar decision to bring this landmark manufacturing facility to North Carolina underscores its commitment to our state and confidence in our state’s talent,” said McCrory, ADDING. “This expansion of the current site and workforce highlights our ability to be a leader in bio-manufacturing at the global level.”
The new site is situated adjacent to Novo Nordisk’s 457,000 square foot Clayton, N.C. facility. Expanded several times since it was inaugurated in 1996, Novo Nordisk’s current plant in Clayton, is one of the company’s strategic production sites responsible for formulation, filling and packaging of diabetes medicines. The plant also assembles and packages the company’s FlexPen and FlexTouch prefilled insulin devices for the U.S. market.
Once the new site becomes operational, the diabetes API production organization in Clayton will be named DAPI-US (Diabetes Active Pharmaceutical Ingredients – US). It will be part of the Danish diabetes API production organization in Kalundborg, which will be named DAPI-Denmark.
http://www.novonordisk-us.com
